Antiplatelet and Anticoagulation Therapy In PCI, An Issue of Interventional Cardiology Clinics, 1st Edition
著者 :
By Dominick J. Angiolillo, MD, PhD and Matthew J. Price, MD
This issue of Interventional Cardiology Clinics, edited by Drs. Dominick Angiolillo and Matthew Price, will focus on Antiplatelet and Anticoagulation Therapy in PCI. The topics covered in this volume will span across pretreatment with antiplatelet ag
...view more
This issue of Interventional Cardiology Clinics, edited by Drs. Dominick Angiolillo and Matthew Price, will focus on Antiplatelet and Anticoagulation Therapy in PCI. The topics covered in this volume will span across pretreatment with antiplatelet agents; optimal duration of antiplatelet therapy after PCI; Cangrelor and its role in percutaneous coronary intervention; Ticagrelor and its effects beyond the P2Y12 receptor; dyspnea and Reversibly-binding P2Y12 antagonists; PAR receptor inhibition post-PCI; switching P2Y12 receptor inhibiting therapies; antiplatelet and antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting; antithrombotic therapy to reduce ischemic events in ACS patients undergoing PCI; and the current role of platelet function testing in PCI and CABG, among other topics.
This issue of Interventional Cardiology Clinics, edited by Drs. Dominick Angiolillo and Matthew Price, will focus on Antiplatelet and Anticoagulation Therapy in PCI. The topics covered in this volume will span across pretreatment with antiplatelet agents; optimal duration of antiplatelet therapy after PCI; Cangrelor and its role in percutaneous coronary intervention; Ticagrelor and its effects beyond the P2Y12 receptor; dyspnea and Reversibly-binding P2Y12 antagonists; PAR receptor inhibition post-PCI; switching P2Y12 receptor inhibiting therapies; antiplatelet and antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting; antithrombotic therapy to reduce ischemic events in ACS patients undergoing PCI; and the current role of platelet function testing in PCI and CABG, among other topics.
著者情報
By Dominick J. Angiolillo, MD, PhD, University of Florida College of Medicine-Jacksonville and Matthew J. Price, MD, Scripps Clinic, La Jolla CA
https://shop.elsevier.jp/antiplatelet-and-anticoagulation-therapy-in-pci-an-issue-of-interventional-cardiology-clinics-9780323482820.html302393Antiplatelet and Anticoagulation Therapy In PCI, An Issue of Interventional Cardiology Clinicshttps://secure-ecsd.elsevier.com/covers/80/Tango2/large/9780323482820.jpg88208820JPYInStock/Medicine & Surgery/Cardiology/eBooks/Medicine/Cardiology/eBooks/eBooks/Medicine/Cardiology/Medicine/Cardiology/Product Format/E-Book/Product Format/E-Book/Product Format/E-Book/Product Format/E-Book443121243887245054569505466552550405259850580358059368005936822593682759368321418269243350884886536505455351451205259833579989258035265936799593680959368235936828This issue of Interventional Cardiology Clinics, edited by Drs. Dominick Angiolillo and Matthew Price, will focus on Antiplatelet and Anticoagulation Therapy in PCI. The topics covered in this volume will span across pretreatment with antiplatelet agents; optimal duration of antiplatelet therapy after PCI; Cangrelor and its role in percutaneous coronary intervention; Ticagrelor and its effects beyond the P2Y12 receptor; dyspnea and Reversibly-binding P2Y12 antagonists; PAR receptor inhibition post-PCI; switching P2Y12 receptor inhibiting therapies; antiplatelet and antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting; antithrombotic therapy to reduce ischemic events in ACS patients undergoing PCI; and the current role of platelet function testing in PCI and CABG, among other topics. This issue of Interventional Cardiology Clinics, edited by Drs. Dominick Angiolillo and Matthew Price, will focus on Antiplatelet and Anticoagulation Therapy in PCI. The topics covered in this volume will span across pretreatment with antiplatelet agents; optimal duration of antiplatelet therapy after PCI; Cangrelor and its role in percutaneous coronary intervention; Ticagrelor and its effects beyond the P2Y12 receptor; dyspnea and Reversibly-binding P2Y12 antagonists; PAR receptor inhibition post-PCI; switching P2Y12 receptor inhibiting therapies; antiplatelet and antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting; antithrombotic therapy to reduce ischemic events in ACS patients undergoing PCI; and the current role of platelet function testing in PCI and CABG, among other topics.00add-to-cart97803234828202016専門医By Dominick J. Angiolillo, MD, PhD and Matthew J. Price, MD20171E-BookElsevier02016/11/26IN STOCKBy <STRONG>Dominick J. Angiolillo</STRONG>, MD, PhD, University of Florida College of Medicine-Jacksonville and <STRONG>Matthew J. Price</STRONG>, MD, Scripps Clinic, La Jolla CAE-BookE-BookThe Clinics: Internal MedicineS013Cardiology, Medicine米国いいえいいえいいえいいえいいえ選択してください選択してくださいいいえいいえ選択してください
